BioWorld® - Medical Device Daily

More documents

Recommendations

Info

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information BioMerieux INDUSTRY Assay kits and components MAbs, polyclonals, and proteins Specialty plastic labware KEY PERSONNEL: 595 Anglum Road Hazelwood MO 63042-2320, US Phone: (314) 731-8500; Fax: (314) 731-8678 Toll-free phone: (800) 634-7656 Web: www.biomerieux-vitek.com E-mail: tim.malloy@na.biomerieux.com Alain Merieux; Chairman and CEO, bioMerieux sa Tom O'Brien; Director, U.S. Industry Sales Karen Mullen; Sr. Market Manager; Pharma Mike Bullard; National Business Manager, Pharma Lee Doughton; Corporate Account Manager, Pharma EMPLOYEES: 710 employees HISTORY: Began biotech R&D in 1966 Founded in 1977 FACILITIES: Headquarters in St. Louis, Mo. Manufacturing facilities in St. Louis, Mo., and Rockland, Mass. STOCK-FINANCIAL HISTORY: Privately held by parent SUBSIDIARIES/DIVISIONS: BioMerieux Inc. 100 Rodolphe Street Durham, NC 27717, USA Phone: (919) 620-2000 SUBSIDIARY OF: BioMerieux SA (see separate entry) BUSINESS STRATEGY: Develop and manufacture microbiology and immunoassays AGREEMENTS: Name Products Content of Agreement Date Affymetrix Inc. DNA probe arrays using development 9/96 Affymetrix GeneChip agreement for technology bacteriology testing Gen-Probe Inc. probe assays for Vidas development agreement 5/97 MRL The Surveillance global surveillance 5/97 Network (TSN) partnership OraVax Inc. human diagnostic exclusive 11/96 products incorporating worldwide licensing CagA for H. pylori detection agreement RESEARCH & DEVELOPMENT: Microbiology, immunoassays, pharmacy PRODUCTS ON MARKET: Vitek Vidas mini-Vidas API Slidex Chromogenic media TheraTrac 2 TSN Copyright ©2006 AHC Media ® 74
BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information BioMerieux SA 376 Chemin de l'Orme Marcy l'Etoile F-69280, France Phone: +33 04 78 87 20 00; Fax: +33 04 78 87 20 90 Web: www.biomerieux.com KEY PERSONNEL: Alain Merieux; Chairman Benoît Adelus; Exec. VP Christophe Merieux; Sr. VP, R&D and <strong>Medical</strong> Affairs Frederic Benoliel; Corp. VP, Asia Pacific Thierry Bernard; Corp. VP, Europe, Middle East, Africa Xavier Fargetton; Corp. VP, Global Marketing and Strategic Development Jocelyne Latour; Corp. VP, Quality Assurance and Regulatory Affairs Jean-Francois de Lavison; Corp. VP, Public and International Affairs Marc Mackowiak; Corp. VP, R&D Pierre Piffeteau; Corp. VP, Industrial Operations and Purchasing Alexandre Merieux; Corp. VP, Industrial Microbiology Henri Thomasson; Corp. VP, Finance Peter Kaspar; Corp. VP and Head, Molecular Biology EMPLOYEES: 5,300+ employees HISTORY: Founded in 1897 Began biotech R&D in 1963 Changed name from Institut Merieux (1974) Acquired API System (1987) Acquired VITEK Systems (1988) Acquired the diagnostics unit of Organon Teknika, a division of Akzo Nobel (2001) Sold its hemostasis range of products to Trinity Biotech plc (6/06) FACILITIES: Corporate headquarters facilities in France with 2,100 employees Operations and facilites in over 130 countries, with more than 110 distributors Nine research centers worldwide STOCK-FINANCIAL HISTORY: Listed on the Premier Marche of Euronext, Paris (FR0010096479 – BIM) Net sales EUR993.6M (YE 05) compared to EUR929.3M (YE 04) Net income EUR90.1M (YE 05) compared to EUR79.7M (YE 04) Earnings per share EUR2.28/share (YE 05) compared to EUR2.04/share (YE 04) Total assets EUR906.1M (YE 05) compared EUR838.6M (YE 04) SUBSIDIARIES/DIVISIONS: Thirty-three subsidiaries in 130 countries Two business areas: Clinical diagnostics: Focuses on diagnosing infectious diseases, such as hepatitis B, HIV, tuberculosis, respiratory infections and increasingly pathologies, such as cardiovascular diseases and cancers Industrial diagnostics: Focuses on controlling the microbiological quality of an industrial or environmental sample BUSINESS STRATEGY: Become a key player in the in vitro diagnostics field of infectious diseases and other pathologies, such as cardiovascular diseases or cancers. It has implemented the following strategy: -Focusing its development on applications with a high potential -Launching new products to better satisfy the needs of patients and the imperatives of public health in general -Reinforcing its worldwide network to seize growth opportunities -Continuing with its sustained effort in research and development -Investing in new technologies via strategic alliances and targeted purchases that guarantee growth and technological independence -Pursuing a balanced financial strategy to seize on growth opportunities Copyright ©2006 AHC Media ® 75
Page 1 and 2:
BioWorld ® INDUSTRIAL BIOTECHNOLGY
Page 3 and 4:
BioWorld Industrial Biotechnology S
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24: BioWorld Industrial Biotechnology S
Page 39 and 40: Applera Corp. BioWorld Industrial B
Page 73: BioWorld Industrial Biotechnology S
Page 99 and 100: CABI BioWorld Industrial Biotechnol
Page 107 and 108: Cargill Inc. BioWorld Industrial Bi
Page 109 and 110: Ceapro Inc. BioWorld Industrial Bio
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Digene Corp. BioWorld Industrial Bi
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
EvoGenix Ltd. BioWorld Industrial B
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Galderma SA BioWorld Industrial Bio
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Hercules Inc. BioWorld Industrial B
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Iogen Corp. BioWorld Industrial Bio
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Lake States BioWorld Industrial Bio
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Paprican BioWorld Industrial Biotec
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Primm S.R.L. BioWorld Industrial Bi
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Prokaria ehf BioWorld Industrial Bi
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Recordati SpA BioWorld Industrial B
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Symbio BioWorld Industrial Biotechn
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
UVP Inc. BioWorld Industrial Biotec
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
YMC Co. Ltd. BioWorld Industrial Bi
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
show all

BioWorld® - Medical Device Daily

Create successful ePaper yourself

Delete template?

Save as template?